The new complaint echoes one Par faced from Mutual Pharmaceutical Co. in April 2012, about the time Takeda acquired Mutual parent URL Pharma for $800M. After that lawsuit, Par voluntarily dropped its abbreviated new drug application with the U.S. Food and Drug Administration, but notified Takeda in July that it was renewing...